They found that:
- The antimicrobials market can be revitalized by pull incentives worth between US$2.2 and US$4.5 billion per drug, paid over 10 years. This can be achieved if G7 countries contribute their fair share of funding to new incentives. As this year’s G7 Leader, Roundtable Participants called on Japan, especially, to meet its fair share of global funding (US$443 million per drug).
- It is estimated that the world needs at least six new antimicrobial innovations per decade to make serious progress to solve the AMR crisis. This will only be possible through further funding for “pull” incentives, which delink revenue from sales volume, making it possible for manufacturers to support continued antimicrobial innovation without needing to actively sell new antimicrobials.
- Antimicrobial incentives produce tremendous returns on investment for the societies that create them. Pull incentives will help countries around the world avoid serious economic and fiscal problems in the future due to AMR.